Statement by the Board of Directors and the Executive Board

Independent auditor's report

Statement by the Board of Directors and the Executive Board

Independent auditor's report

Management's review

Management's review

Management's review

Financial statements 1 January – 31 December

Financial statements 1 January – 31 December

Financial statements 1 January – 31 December

Financial statements 1 January – 31 December

Financial statements 1 January – 31 December

Annual report 2024

Contents

Statement by the Board of Directors and the Executive Board

Independent auditor's report

Management's review

Financial statements 1 January – 31 December

Statement by the Board of Directors and the Executive Board

Independent auditor's report

Management's review

Management's review

Management's review

Financial statements 1 January – 31 December

Financial statements 1 January – 31 December

Financial statements 1 January – 31 December

Financial statements 1 January – 31 December

Financial statements 1 January – 31 December

Company details

Financial highlights

Operating review

Income statement

Balance sheet

Balance sheet

Statement of changes in equity

Notes

Income statement

Balance sheet

Company details

Financial highlights

Operating review

Income statement

Balance sheet

Balance sheet

Statement of changes in equity

Notes

Income statement

Balance sheet

To the shareholder of PreMed A/S

Company details

Financial highlights

Operating review

Income statement

Balance sheet

Statement of changes in equity

Notes

To the shareholder of PreMed A/S

Opinion

Basis for Opinion

Management's responsibility for the financial statements

Auditor's responsibilities for the audit of the financial statements

Statement on the Management's review

Board of Directors

Executive Board

Audit

Principal activities

Development in activities and financial position

Outlook

Events after the balance sheet date

Control

Related party transactions

Loss for the year (including comparison with forecasts previously announced)

Investments

Unexpected expenses

Stable and profitable future operations

Good working environment and high-quality ambulance services

Municipal Aid Depots

Pending disputes

1

Accounting policies

Omission of presentation of consolidated financial statements

Omission of cash flow statement

Foreign currency translation

Revenue

Cost of sales

Other external costs

Staff costs

Financial income and expenses

Tax on loss for the year

Intangible assets

Patents, licences and trademarks

Property, plant and equipment

Leases

Financial assets

Impairment of fixed assets

Receivables

Corporation tax and deferred tax

Prepayments

Cash at bank and in hand

Liabilities

Deferred income

2

Staff costs

3

Financial expenses

PreMed A/S

Annual report 2024

CVR no. 39 71 21 05

	Management's review
	Company details
	Financial highlights
	Operating review

	Financial statements 1 January – 31 December
	Income statement
	Balance sheet
	Statement of changes in equity
	Notes

PreMed A/S

Annual report 2024

CVR no. 39 71 21 05

	The Board of Directors and the Executive Board have today discussed and approved the annual report for PreMed A/S for the financial year 1 January - 31 December 2024.

	The annual report has been prepared in accordance with the Danish Financial Statements Act.

	In our opinion, the financial statements give a true and fair view of the Company's assets, liabilities and financial position at 31 December 2024 and of the results of the Company's operations for the financial year 1 January - 31 December 2024.

	Further, in our opinion, the Management's review gives a fair review of the development in the Company's activities and financial matters, of the results for the year and of the Company's financial position.

	We recommend that the annual report be approved at the annual general meeting.

	Kolding, 1 May 2025

Executive Board:
Anders Vikke Director
Board of Directors:
Vesa Kämäräinen Chairman	Katariina Hannele Matveinen	Markus Caj Sebastian Ulfstedt

PreMed A/S

Annual report 2024

CVR no. 39 71 21 05

	Opinion

	We have audited the financial statements of PreMed A/S for the financial year 1 January - 31 December 2024, comprising income statement, balance sheet, statement of changes in equity and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

	In our opinion, the financial statements give a true and fair view of the Company's assets, liabilities and financial position at 31 December 2024 and of the results of the Company's operations for the financial year 1 January - 31 December 2024 in accordance with the Danish Financial Statements Act.

	Basis for Opinion

	We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report.

	We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code.

	We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

	Management's responsibility for the financial statements

	Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control that Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

	In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

	Auditor's responsibilities for the audit of the financial statements

	Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements in Denmark will always detect a material misstatement when it exists. Misstatements may arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of financial statement users made on the basis of these financial statements.

	As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also

	●	identify and assess the risks of material misstatement of the company financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.

	●	obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.

	●	evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.

	●	conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

	●	evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

	We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

	Statement on the Management's review

	Management is responsible for the Management's review.

	Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.

	In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

	Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.

	Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review.

Fredericia, 1 May 2025

KPMG

Statsautoriseret Revisionspartnerselskab

CVR no. 25 57 81 98

Nikolaj Møller Hansen

State Authorised Public Accountant

mne33220

PreMed A/S

Annual report 2024

CVR no. 39 71 21 05

	PreMed A/S
	Jernet 13
	DK-6000 Kolding


	Website:	www.premed.dk
	E-mail:	info@premed.dk

	CVR no.:	39 71 21 05
	Established:	8 July 2018
	Registered office:	Kolding
	Financial year:	1 January - 31 December

	Board of Directors

	Vesa Kämäräinen, Chairman
	Katariina Hannele Matveinen
	Markus Caj Sebastian Ulfstedt

	Executive Board

	Anders Vikke, Director

	Audit

	KPMG
	Statsautoriseret Revisionspartnerselskab
	Vesterballevej 27, 2
	DK-7000 Fredericia
	CVR no. 25 57 81 98

PreMed A/S

Annual report 2024

CVR no. 39 71 21 05

DKK	2024	2023	2022	2021	2020

Gross profit	116,514,864 116,514,864	114,540,234 114,540,234	82,484,353 82,484,353	3,680,972 3,680,972	2,138,998 2,138,998
Profit/loss before financial income and expenses	-4,762,082 4,762,082	2,441,777 2,441,777	-3,589,693 3,589,693	-2,686,817 2,686,817	-583,775 583,775
Loss from financial income and expenses	-3,359,280 3,359,280	-3,455,544 3,455,544	-4,298,191 4,298,191	-669,628 669,628	-145,346 145,346
Loss for the year	-8,203,343 8,203,343	-854,348 854,348	-7,663,395 7,663,395	-2,660,564 2,660,564	-570,198 570,198

Total assets	45,158,567 45,158,567	58,599,671 58,599,671	88,219,461 88,219,461	34,373,460 34,373,460	4,043,572 4,043,572
Investments in property, plant and equipment	0 0	85,499 85,499	40,371,543 40,371,543	21,390,440 21,390,440	1,451,467 1,451,467
Equity	-20,343,691 20,343,691	-12,140,348 12,140,348	-11,286,000 11,286,000	-3,622,608 3,622,608	-176,354 176,354

Current ratio	49.6% 0.496	63.2% 0.632	75.3% 0.753	32.3% 0.323	144.3% 1.443
Solvency ratio	-45.0% 0.450	-20.7% 0.207	-12.8% 0.128	-10.5% 0.105	-4.4% 0.044

Average number of full-time employees	203	187	135	12	6

	The financial ratios have been calculated as follows:


	Current ratio	Current assets x 100 / Current liabilities


	Solvency ratio	Equity at year end x 100 / Total equity and liabilities at year end

PreMed A/S

Annual report 2024

CVR no. 39 71 21 05

	Principal activities

	The Company's pricipal activities comprise assistance, rescue, training, health and other service operations as well as any other activities which the Board of Directors deems to be related to.

	The range of services are within the following segments:

	- Municipal Aid Depots

	- Ambulance services and patient transportation

	Development in activities and financial position

	Loss for the year (including comparison with forecasts previously announced)

	The Company's income statement for 2024 shows a loss of DKK 8,203,343 as against a loss of DKK 854,348 in 2023. Equity in the Company's balance sheet at 31 December 2024 stood at DKK -20,343,691 as against DKK -12,140,348 at 31 December 2023.

	The financial year was not in line with forecast, and results for the year are considered unsatisfactory.

	The Company's equity is negative. Management expects equity to be reestablished over future earnings.

	Investments

	Just as expected, PreMed A/S has invested heavily in establishing new bases for its ambulance services. More than 140 employees have been onboarded, and the Company made fairly large investments in ambulances, inventory, other equipment and uniforms in 2022.

	Unexpected expenses

	Financial results for 2024 were less satisfactory than expected due to increase staff costs and unexpected contract costs.

	Stable and profitable future operations

	In 2024, a good and stable ambulance operation has been consolidated in an industry which nationally lacks several hundred employees. Management finds that very satisfactory.

	Good working environment and high-quality ambulance services

	PreMed A/S went into ambulance service to create an operation with a good and developing working environment for its employees and to provide high-quality ambulance services to citizens. This ambition has been fulfilled in less than two years.

	Municipal Aid Depots

	Aid Depots in Kolding and Nyborg employ approx. 15 full-time employees. Operations are stable, and results are positive.

	Pending disputes

	The entity is part of two ongoing disputes. Reference is made to disclosure 14.

	Outlook

Management's focus is on continued consolidating operations and on the organisation. The overall benchmarks are to ensure stable operations with high quality, happy employees and a profitable business. In this context, staff satisfaction reached a score of 3.8 out of 4 for the first 35 months of operations. In 2025, we expect a turnover to be stable however the ambulance market environment is challenging for making a good result. The expectations for 2025 are a gross profit in the range of DKK 145,000 - 155,000 thousand and a result after tax in the range of DKK -5,000 thousand - 0. Especially the result contains uncertainty.

	Events after the balance sheet date

	No events have occurred after the balance sheet date of material importance to the annual report for 2024.

PreMed A/S

Annual report 2024

CVR no. 39 71 21 05

DKK

Note

2024

2023

Gross profit		116,514,864 116,514,864	114,540,234 114,540,234
Staff costs	2	-115,784,188 115,784,188	-106,625,664 106,625,664
Depreciation of property, plant and equipment and amortisation of intangible assets		-5,492,758 5,492,758	-5,472,793 5,472,793
Profit/loss before financial income and expenses		-4,762,082 4,762,082	2,441,777 2,441,777
Other financial income		207,488 207,488	192,475 192,475
Other financial expenses	3	-3,566,768 3,566,768	-3,648,019 3,648,019
Loss before tax		-8,121,362 8,121,362	-1,013,767 1,013,767
Tax on loss for the year	4	-81,981 81,981	159,419 159,419
Loss for the year	5	-8,203,343 8,203,343	-854,348 854,348

PreMed A/S

Annual report 2024

CVR no. 39 71 21 05

DKK

Note

31/12 2024

31/12 2023

ASSETS
Fixed assets
Intangible assets	6
Patents, licences and trademarks		64,680 64,680	168,870 0
Property, plant and equipment	7
Fixtures, fittings, tools and equipment		16,561,406 16,561,406	21,655,623 0
Leasehold improvements		571,310 571,310	865,661 0
		17,132,716 17,132,716	22,521,284 22,521,284
Financial assets
Equity investments in group entities	8	40,000 40,000	40,000 0
Deposits		1,642,590 1,642,590	2,087,948 0
		1,682,590 1,682,590	2,127,948 2,127,948
Total fixed assets		18,879,986	24,818,102


Current assets
Receivables
Trade receivables		2,104,980 2,104,980	18,974,632 0
Receivables from group entities		9,706,306 9,706,306	5,389,596 0
Deferred tax assets	9	82,091 82,091	722,345 0
Other receivables		561,495 561,495	908,200 0
Prepayments	10	2,064,047 2,064,047	413,038 0
		14,518,919 14,518,919	26,407,811 26,407,811
Cash at bank and in hand		11,759,662 11,759,662	7,373,758 7,373,758
Total current assets		26,278,581	33,781,569
TOTAL ASSETS		45,158,567	58,599,671

PreMed A/S

Annual report 2024

CVR no. 39 71 21 05

DKK

Note

31/12 2024

31/12 2023

Current liabilities
Trade payables		4,177,693 4,177,693	2,533,161 2,533,161
Payables to group entities	12	3,973,739 3,973,739	5,432,142 5,432,142
Lease obligations	12	4,764,000 4,764,000	4,764,000 4,764,000
Other payables, including taxes payable		8,237,838 8,237,838	9,292,060 9,292,060
Deferred income	13	31,845,506 31,845,506	31,451,174 31,451,174
		52,998,776 52,998,776	53,472,537 53,472,537
Total liabilities		65,502,258	70,740,019
TOTAL EQUITY AND LIABILITIES		45,158,567	58,599,671

PreMed A/S

Annual report 2024

CVR no. 39 71 21 05

DKK	Contributed capital	Retained earnings	Total
Equity at 1 January 2024	400,000	- 12,540,348	-12,140,348
Transferred over the distribution of loss	0	- 8,203,343	-8,203,343
Equity at 31 December 2024	400,000	- 20,743,691	-20,343,691

PreMed A/S

Annual report 2024

CVR no. 39 71 21 05

1	Accounting policies

	The annual report of PreMed A/S for 2024 has been prepared in accordance with the provisions applying to reporting class C medium-sized under the Danish Financial Statements Act.

The accounting policies used in the preparation of the financial statements are consistent with those of last year.

	Omission of presentation of consolidated financial statements

Pursuant to section 112(1) of the Danish Financial Statements Act, no consolidated financial statements have been prepared. The financial statements of PreMed A/S and group entities are included in the consolidated financial statements of 9Lives Group OY, Kutomotie 2 00380, Helsinki, Uusimaa Finland.

	Omission of cash flow statement

Pursuant to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The Company's cash flows are included in the cash flow statement in the consolidated financial statements of 9Lives Group OY.

	Foreign currency translation

	On initial recognition, transactions denominated in foreign currencies are translated at the exchange rates at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and the date of payment are recognised in the income statement as financial income or financial expenses.

	Receivables, payables and other monetary items denominated in foreign currencies are translated at the exchange rates at the balance sheet date. The difference between the exchange rates at the balance sheet date and the date at which the receivable or payable arose or was recognised in the latest financial statements is recognised in the income statement as financial income or financial expenses.

	Revenue

	Income from the sale of service is recognised in revenue when delivery and transfer of risk to the buyer have taken place, and the income may be measured reliably and is expected to be received.

	Revenue is measured at the fair value of the agreed consideration excluding VAT and taxes charged on behalf of third parties. All discounts granted are deducted from revenue.

	Cost of sales

	Cost of sales comprises costs incurred to generate revenue for the year.

	Other external costs

	Other external costs comprise costs for distribution and sales costs, administrative expenses, costs of premises, bad debts, operating leases, etc.

	Staff costs

	Staff costs comprise wages and salaries, including holiday allowance, pension and other social security costs.

	Financial income and expenses

	Financial income and expenses comprise interest income and expense, financial costs regarding finance leases, gains and losses on securities, payables and transactions denominated in foreign currencies, amortisation of financial assets and liabilities as well as surcharges and refunds under the on-account tax scheme, etc.

	Tax on loss for the year

	Tax for the year comprises current tax for the year and changes in deferred tax, including changes in tax rates. The tax expense relating to the profit/loss for the year is recognised in the income statement at the amount attributable to the profit/loss for the year and directly in equity at the amount attributable to entries directly in equity.

	Intangible assets

	Patents, licences and trademarks

	Patents and licences are measured at cost less accumulated amortisation and impairment losses. Patents and licences are amortised on a straight-line basis over the remaining life.

	The amortisation period for software is 3 years.

	Gains and losses on the disposal of intangible assets are determined as the difference between the selling price less selling costs and the carrying amount at the date of disposal.

	Gains and losses are recognised in the income statement as other operating income or other operating costs, respectively.

	Property, plant and equipment

	Plant and machinery and fixtures and fittings, tools and equipment are measured at cost less accumulated depreciation and impairment losses.

	Cost comprises the purchase price and any costs directly attributable to the acquisition until the date on which the asset is available for use. Indirect production overheads and borrowing costs are not recognised in cost.

	Where individual components of an item of property, plant and equipment have different useful lives, they are accounted for as separate items, which are depreciated separately.

	The basis of depreciation is cost less any projected residual value after the end of the useful life. Depreciation is provided on a straight-line basis over the estimated useful life. The estimated useful lives are as follows:

	Fixtures, fittings, tools and equipment		6 years
	Leasehold improvements		5 years

	The useful life and residual value are reassessed annually. Changes are treated as accounting estimates, and the effect on depreciation is recognised prospectively.

	Gains and losses on the disposal of property, plant and equipment are stated as the difference between the selling price less selling costs and the carrying amount at the date of disposal. Gains and losses are recognised in the income statement as other operating income or other operating costs, respectively.

	Leases

	On initial recognition, leases for fixed assets that transfer substantially all risks and rewards incident to ownership to the Company (finance leases) are recognised in the balance sheet at the lower of fair value and the net present value of future lease payments. When the net present value is calculated, the interest rate implicit in the lease or the incremental borrowing rate is used as the discount factor. Assets held under finance leases are subsequently depreciated as the Company's other fixed assets.

	The capitalised lease obligation is recognised in the balance sheet as a liability at amortised cost, allowing the interest element of the lease payment to be recognised in the income statement over the term of the lease.

	All other leases are accounted for as operating leases. Payments relating to operating leases and other leases are recognised in the income statement over the term of the lease. The Company's total obligation relating to operating leases and other leases is disclosed as contractual obligations and contingencies, etc.

	Financial assets

	Equity investments in group entities are measured at cost. In case of indication of impairment, an impairment test is conducted. When the cost exceeds the recoverable amount, write-down is made to this lower value.

	Deposits are recognised at amortised cost.

	Impairment of fixed assets

	The carrying amount of intangible assets and property, plant and equipment as well as equity investments in group entities is subject to an annual test for indications of impairment other than the decrease in value reflected by depreciation or amortisation.

	Impairment tests are conducted of individual assets or groups of assets when there is an indication that they may be impaired. Write-down is made to the recoverable amount if this is lower than the carrying amount.

	The recoverable amount is the higher of an asset's net selling price and its value in use. The value in use is determined as the present value of the forecast net cash flows from the use of the asset or the group of assets, including forecast net cash flows from the disposal of the asset or the group of assets after the end of the useful life.

	Receivables

	Receivables are measured at amortised cost.

	Write-down is made for bad debt losses where there is an objective indication that a receivable has been impaired. If there is an objective indication that an individual receivable has been impaired, write-down is made on an individual basis.

	Corporation tax and deferred tax

	Current tax payable and receivable is recognised in the balance sheet as tax computed on the taxable income for the year, adjusted for tax on the taxable income of prior years and for tax paid on account.

	Deferred tax is measured using the balance sheet liability method on all temporary differences between the carrying amount and the tax value of assets and liabilities measured on the planned use of the asset or settlement of the liability, respectively. However, deferred tax is not recognised on temporary differences relating to office buildings non-deductible for tax purposes and other items where temporary differences arise at the date of acquisition without affecting either profit/loss or taxable income.

	Deferred tax assets, including the tax value of tax loss carryforwards, are recognised at the expected value of their utilisation within the foreseeable future; either as a set-off against tax on future income or as a set-off against deferred tax liabilities in the same legal tax entity. Any deferred net assets are measured at net realisable value.

	Deferred tax is measured in accordance with the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Changes in deferred tax as a result of changes in tax rates are recognised in the income statement or equity, respectively.

	Prepayments

	Prepayments comprise prepayment of costs incurred relating to subsequent financial years.

	Cash at bank and in hand

	Cash at bank and in hand comprise cash and bank deposits.

	Liabilities

	Financial liabilities are recognised at the date of borrowing at cost, corresponding to the proceeds received less transaction costs paid. In subsequent periods, the financial liabilities are measured at amortised cost, corresponding to the capitalised value using the effective interest rate. Accordingly, the difference between cost and the nominal value is recognised in the income statement over the term of the loan together with interest expenses.

	Finance lease obligation comprise the capitalised residual lease obligation of finance leases.

	Other liabilities are measured at amortised cost.

	Deferred income

	Deferred income comprises payments received regarding income in subsequent years.

2	Staff costs

DKK

2024

2023

Wages and salaries	100,372,285 100,372,285	93,060,326 93,060,326
Pensions	12,672,433 12,672,433	11,252,493 11,252,493
Other social security costs	2,739,470 2,739,470	2,312,845 2,312,845
	115,784,188	106,625,664

Average number of full-time employees

203

187

Staff costs include remuneration of the Company's Executive Board and Board of Directors totaling DKK 1,434 thousand. In 2023 remuneration of Executive Board and the Board of Directors is not disclosed in accordance with section 98 B (3) of the Danish Financial Statements Act.

3	Financial expenses

DKK

2024

2023

Interest expense to group entities	3,112,364 3,112,364	3,268,126 3,268,126
Exchange losses	248,501 248,501	375,589 375,589
Other financial expenses	205,903 205,903	4,304 4,304
	3,566,768	3,648,019

4	Tax on loss for the year

DKK

2024

2023

Deferred tax adjustment for the year	640,254 640,254	-159,419 159,419
Refund in joint taxation arrangement	-558,273 558,273	0 0
	81,981	-159,419

5	Proposed distribution of loss

DKK

2024

2023

	Retained earnings			- 8,203,343		- 854,348
				-8,203,343		-854,348

6	Intangible assets

	DKK		Patents, licences and trademarks
	Cost at 1 January 2024		478,139
	Cost at 31 December 2024		478,139
	Amortisation and impairment losses at 1 January 2024		- 309,269
	Amortisation		- 104,190
	Amortisation and impairment losses at 31 December 2024		- 413,459
	Carrying amount at 31 December 2024		64,680

7	Property, plant and equipment

DKK	Fixtures, fittings, tools and equipment	Leasehold improvements	Total
Cost at 1 January 2024	30,663,820	1,585,774	32,249,594
Cost at 31 December 2024	30,663,820	1,585,774	32,249,594
Depreciation and impairment losses at 1 January 2024	- 9,008,197	- 720,113	-9,728,310
Depreciation for the year	- 5,094,217	- 294,351	-5,388,568
Depreciation and impairment losses at 31 December 2024	- 14,102,414	- 1,014,464	- 15,116,878
Carrying amount at 31 December 2024	16,561,406	571,310	17,132,716

Assets held under finance leases

15,138,661

0

15,138,661

8	Financial assets

	DKK		Equity investments in group entities
	Cost at 1 January 2024		40,000
	Cost at 31 December 2024		40,000
	Carrying amount at 31 December 2024		40,000

Name/legal form	Registered office	Equity interest	Equity	Profit/loss for the year
			DKK	DKK
Equity investments in group entities:
PreMed Fleet ApS	Jernet 13, 6000 Kolding	100%	-284,765	-255,121

9	Deferred tax

DKK

31/12 2024

31/12 2023

Deferred tax at 1 January	722,345 722	1,302,632 1,302,632
Deferred tax adjustment for the year in the income statement	-640,254 -640	-580,287 -580,287
	82,091	722,345

	The company has an unrecognized tax loss carry forward of DKK 7,701 thousand (22% tax value amounts DKK 1,694 thousand). Based on current performance of the company it is highly uncertain that tax loss carry forward can be used and has therefore not been capitalized.

10	Prepayments

	DKK		31/12 2024		31/12 2023
	Prepaid service		2,064,047 2,064,047		413,038 413,038

11	Contributed capital

	Contributed capital consists of:

	40.000 shares of nom. DKK 1 each.

12	Non-current liabilities

DKK

31/12 2024

31/12 2023

Payables to group entities:
0-1 year	3,973,739	5,432,142
1-5 years	1,440,000	1,440,000
	5,413,739	6,872,142
Lease obligations:
0-1 year	4,764,000	4,764,000
1-5 years	11,063,482	15,827,482
	15,827,482	20,591,482
Total financial debts	21,241,221	27,463,624


Outstanding debt after five years	0	0

The financial debts are recognized in the balance sheet as follows:

Long-term debt	12,503,482	17,267,482
Short-term debt	8,737,739	10,196,142
	21,241,221	27,463,624

	Lease obligations as per the balance sheet are payables to Group entities.

13	Deferred income

	Deferred income of DKK 31,846 thousand (2023: DKK 31,451 thousand) comprise payments received from customers relating to services to be performed in 2025.

14	Contractual obligations, contingencies, etc.

	Contingent liabilities

	PreMed has received a DKK 18 million penalty claim regarding an ongoing contract disagreement. The claim is disputed in its entirety by Management and is not expected to have a significant financial impact on the company, as PreMed A/S has an equal counterclaim.

	Operating lease obligations

The Company has entered into operating leases with a remaining term of 47 months and an average monthly lease payments of DKK 7 thousand, totalling DKK 10,783 thousand.


	As management company, the Company is jointly taxed with other Danish group entities and is jointly and everally liable with other jointly taxed group entities for the payment of income taxes as well as for witholding axes on interest, royalties and dividends falling due for payment. Any subsequent corrections of the taxable ncome subject to joint taxation or withholding taxes on dividends, etc., may entail an increase in the entities' iability. The Group as a whole is not liable to any other parties.

15	Related parties disclosure



	9Lives Group OY, Kutomotie 2 00380, Helsinki, Uusimaa Finland.

	9Lives Group OY holds the majority of the contributed capital in the Company.

	PreMed A/S is part of the consolidated financial statements of 9Lives Group OY, Kutomotie 2 00380, Helsinki, Uusimaa Finland, which is the smallest and largest group, in which the Company is included as a subsidiary.

	The consolidated financial statements of 9Lives Group OY can be obtained by contacting the Company at the above address.



	In accordance with section 98 c(7) of the Danish Financial Statements Act, the Company has not disclosed any related party transactions as they were conducted on an arm's length basis.

16	Events after the balance sheet date

	No events have occurred that are significant for the assessment of the annual report of 31 December 2024.

EQUITY AND LIABILITIES

Contributed capital

400,000 400,000

400,000 400,000

Retained earnings

-20,743,691 20,743,691

-12,540,348 12,540,348

Total equity

-20,343,691 20,343,691

-12,140,348 12,140,348